Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Oct;68(4):702–707. doi: 10.1038/bjc.1993.413

In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis.

C L van der Wilt 1, G W Visser 1, B J Braakhuis 1, R Wedzinga 1, P Noordhuis 1, K Smid 1, G J Peters 1
PMCID: PMC1968601  PMID: 8398696

Abstract

A class of new 5-fluorouracil (FU) analogues, the 5-fluoro-5,6-dihydro-6- alkoxy-uracils was synthesised with a modification at the 6-position of the pyrimidine ring. At this position the analogues have a hydroxy or alkoxy group of different chain lengths either in the cis- or trans-configuration. The antiproliferative effect of these compounds was tested on five cell lines of different origin. Generally, the analogues with a cis-configuration had a higher activity than those with a trans-configuration. The growth inhibitory effect of the compounds decreased with increasing alkoxy chain length, but the compound with a hydroxy group had the lowest growth inhibitory effect. One analogue, cis-5-F-5,6-dihydro-6-methoxy-uracil had a higher antiproliferative effect than FU in one of the cell lines. Effects on thymidylate synthase (TS), the possible target of these analogues, were evaluated by thymidine rescue of growth inhibition and incorporation of tritiated deoxyuridine (3H-UdR) into DNA. In solid tumour cell lines addition of TdR reversed the antiproliferative effect. Inhibition of TS in intact cells was determined by measuring 3H-UdR incorporation in two cell lines. The effect of cis-5-F-5,6-dihydro-6-methoxy-uracil on incorporation of 3H-UdR was 2- to 5-fold stronger than that of FU in both cell lines. All other compounds produced a higher 3H-UdR incorporation than FU both at equimolar and equi-toxic concentration. Concluding from these results we regard cis-5-F-5,6-dihydro-6-methoxy-uracil as the most promising FU analogue of this series, because of its higher antiproliferative activity than FU and marked inhibition of TS in intact cells.

Full text

PDF
702

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blokhina N. G., Vozny E. K., Garin A. M. Results of treatment of malignant tumors with ftorafur. Cancer. 1972 Aug;30(2):390–392. doi: 10.1002/1097-0142(197208)30:2<390::aid-cncr2820300214>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  2. Braakhuis B. J., Visser G. W., Stringer I., Peters G. J. In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides. Eur J Cancer. 1991;27(3):250–253. doi: 10.1016/0277-5379(91)90508-b. [DOI] [PubMed] [Google Scholar]
  3. Cook A. F., Holman M. J., Kramer M. J., Trown P. W. Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides. J Med Chem. 1979 Nov;22(11):1330–1335. doi: 10.1021/jm00197a010. [DOI] [PubMed] [Google Scholar]
  4. Corbett T. H., Griswold D. P., Jr, Roberts B. J., Peckham J. C., Schabel F. M., Jr Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975 Sep;35(9):2434–2439. [PubMed] [Google Scholar]
  5. Diasio R. B., Harris B. E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989 Apr;16(4):215–237. doi: 10.2165/00003088-198916040-00002. [DOI] [PubMed] [Google Scholar]
  6. HEIDELBERGER C., GRIESBACH L., CRUZ O., SCHNITZER R. J., GRUNBERG E. Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2'-deoxyuridine on transplanted tumors. Proc Soc Exp Biol Med. 1958 Feb;97(2):470–475. doi: 10.3181/00379727-97-23777. [DOI] [PubMed] [Google Scholar]
  7. Harrap K. R., Jackman A. L., Newell D. R., Taylor G. A., Hughes L. R., Calvert A. H. Thymidylate synthase: a target for anticancer drug design. Adv Enzyme Regul. 1989;29:161–179. doi: 10.1016/0065-2571(89)90099-x. [DOI] [PubMed] [Google Scholar]
  8. Heidelberger C., Danenberg P. V., Moran R. G. Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol. 1983;54:58–119. [PubMed] [Google Scholar]
  9. Jackman A. L., Alison D. L., Calvert A. H., Harrap K. R. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies. Cancer Res. 1986 Jun;46(6):2810–2815. [PubMed] [Google Scholar]
  10. Keepers Y. P., Pizao P. E., Peters G. J., van Ark-Otte J., Winograd B., Pinedo H. M. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer. 1991;27(7):897–900. doi: 10.1016/0277-5379(91)90142-z. [DOI] [PubMed] [Google Scholar]
  11. Klohs W. D., Steinkampf R. W. Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells. Cancer Res. 1988 Jun 1;48(11):3025–3030. [PubMed] [Google Scholar]
  12. O'Connor B. M., Jackman A. L., Crossley P. H., Freemantle S. E., Lunec J., Calvert A. H. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor. Cancer Res. 1992 Mar 1;52(5):1137–1143. [PubMed] [Google Scholar]
  13. Peters G. J., Laurensse E., Leyva A., Lankelma J., Pinedo H. M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 1986 Jan;46(1):20–28. [PubMed] [Google Scholar]
  14. Peters G. J., Laurensse E., Leyva A., Pinedo H. M. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1869–1881. doi: 10.1016/0277-5379(87)90053-8. [DOI] [PubMed] [Google Scholar]
  15. Peters G. J., van Groeningen C. J. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol. 1991 Jul;2(7):469–480. doi: 10.1093/oxfordjournals.annonc.a057994. [DOI] [PubMed] [Google Scholar]
  16. Peters G. J., van Groeningen C. J., Laurensse E. J., Pinedo H. M. Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxy-uridine-5'-monophosphate. Eur J Cancer. 1991;27(3):263–267. doi: 10.1016/0277-5379(91)90512-c. [DOI] [PubMed] [Google Scholar]
  17. Peters G. J., van Groeningen C. J., van der Wilt C. L., Meijer S., Smid K., Laurensse E., Pinedo H. M. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin Oncol. 1992 Apr;19(2 Suppl 3):26–35. [PubMed] [Google Scholar]
  18. Pieters R., Huismans D. R., Leyva A., Veerman A. J. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett. 1988 Aug 30;41(3):323–332. doi: 10.1016/0304-3835(88)90294-7. [DOI] [PubMed] [Google Scholar]
  19. Pinedo H. M., Peters G. F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol. 1988 Oct;6(10):1653–1664. doi: 10.1200/JCO.1988.6.10.1653. [DOI] [PubMed] [Google Scholar]
  20. Rode W., Zieliński Z., Dzik J. M., Kulikowski T., Bretner M., Kierdaszuk B., Cieśla J., Shugar D. Mechanism of inhibition of mammalian tumor and other thymidylate synthases by N4-hydroxy-dCMP, N4-hydroxy-5-fluoro-dCMP, and related analogues. Biochemistry. 1990 Dec 4;29(48):10835–10842. doi: 10.1021/bi00500a017. [DOI] [PubMed] [Google Scholar]
  21. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  22. Spears C. P., Gustavsson B. G., Berne M., Frösing R., Bernstein L., Hayes A. A. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res. 1988 Oct 15;48(20):5894–5900. [PubMed] [Google Scholar]
  23. Swain S. M., Lippman M. E., Egan E. F., Drake J. C., Steinberg S. M., Allegra C. J. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989 Jul;7(7):890–899. doi: 10.1200/JCO.1989.7.7.890. [DOI] [PubMed] [Google Scholar]
  24. Van der Wilt C. L., Pinedo H. M., Smid K., Peters G. J. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res. 1992 Sep 15;52(18):4922–4928. [PubMed] [Google Scholar]
  25. Weckbecker G. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol Ther. 1991;50(3):367–424. doi: 10.1016/0163-7258(91)90051-m. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES